Search results
When Will Aroa Biosurgery Limited (ASX:ARX) Turn A Profit?
Simply Wall St. via Yahoo Finance· 3 days agoAroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing,...
Xylyx Bio announces exclusive license agreement with Vanderbilt University for donor organ...
WFRV 5 Green Bay· 1 day agoNEW YORK, May 8, 2024 /PRNewswire/ -- Xylyx Bio, a regenerative medicine company developing innovative solutions for tissue and organ repair< ...
RION doses first subject in Phase IIa diabetic foot ulcer therapy trial
Clinical Trials Arena via Yahoo Finance· 2 days agoRegenerative medicine company RION has dosed the first subject in the Phase IIa clinical trial of...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 9 hours agoIn preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen’s antibody based Wnt mimetic also increased detectable tear
Q1 2024 Paragon 28 Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 10 hours agoUltimately, these most recent launches will help advance Paragon 28's portfolio in the fastest growing subsegments in our market and position the Company well for sustainable ...
Earnings call: Integra LifeSciences reports mixed Q1 results, plans growth By Investing.com
Investing.com· 3 days agoIntegra LifeSciences Holdings Corp. (IART), a leading global medical technology company, reported...
Pat Beyer Buys 3,000 Shares of CONMED Co. (NYSE:CNMD) Stock
ETF DAILY NEWS· 6 days agoCONMED Co. (NYSE:CNMD – Get Free Report) COO Pat Beyer acquired 3,000 shares of the stock in a transaction dated Tuesday, April 30th. The stock was acquired at an average price of $68.30 per ...
More people need transplants than there are organ donors. Pigs might be a solution
CNN via Yahoo News· 4 hours agoThe need for transplant organs is immense and growing. Some scientists think animal organs might be...
Earnings call: AxoGen reports 12.9% revenue growth in Q1 2024 By Investing.com
Investing.com· 3 days agoAxoGen, Inc. (NASDAQ:AXGN), a global leader in peripheral nerve repair, has announced a 12.9%...
Longeveron (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call
Digital Journal· 6 days agoThe company's lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell ("MSC") therapy product...-B(TM) has multiple potential mechanisms of action ...
